BUZZ-Curis Inc: Orphan status for lead cancer drug

Mon Apr 6, 2015 7:50am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Drug developer's shares up 10.63 pct at $2.60 premarket

** Says the U.S. FDA has granted orphan status for its lead cancer drug, CUDC-907

** Says drug being tested in early-stage studies; expects to begin mid-stage studies in second half of year

** Orphan status, which is granted to drugs developed to treat rare diseases, gives developer several incentives including a seven-year marketing exclusivity in U.S.

** Up to Thursday's close, stock had risen 57 pct this year